Article Text

Download PDFPDF
Perioperative considerations for patients exposed to hallucinogens
  1. Trent Emerick1,
  2. Tetyana Marshall2,
  3. Thomas Jeff Martin3 and
  4. Doug Ririe3
  1. 1Department of Anesthesiology and Perioperative Medicine, Chronic Pain Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  2. 2Department of Anesthesiology and Perioperative Medicine, UPMC, Pittsburgh, Pennsylvania, USA
  3. 3Pain Mechanisms Lab, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
  1. Correspondence to Dr Trent Emerick, UPMC Pain Management at Falk Medical Building, 3601 5th Avenue, Floor 6, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; emericktd{at}upmc.edu

Abstract

Hallucinogen exposure in patients in the perioperative period presents challenges for anesthesiologists and other anesthesia providers. Acute and chronic exposure to these substances can cause physiological impacts that can affect the function of anesthetic and analgesic medications used during perioperative care. The objective of this narrative review is to educate readers on the wide array of hallucinogens and psychedelics that may influence the perioperative management of patients exposed to these substances. A narrative review of the literature surrounding hallucinogens and psychedelics was completed. Hallucinogens and psychedelics are quite varied in their mechanisms of action and therefore present a variety of perioperative implications and perioperative considerations. Many of these substances increase serotonin levels or act directly at serotonergic receptors. However, there are other relevant actions that may include varied mechanisms from N-methyl-D-aspartate receptor antagonism to stimulation of muscarinic receptors. With hallucinogen exposure rates on the rise, understanding the effects of hallucinogens is important for optimizing management and reducing risks perioperatively for patients with acute or chronic exposure.

  • Neurotransmitter Agents
  • Drug-Related Side Effects and Adverse Reactions
  • Pharmacology

Data availability statement

Data sharing not applicable as no datasets generated and/or analyzed for this study.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data sharing not applicable as no datasets generated and/or analyzed for this study.

View Full Text

Footnotes

  • Twitter @TrentDEmerick

  • Contributors TE, TJM, and DR helped conceptualize the manuscript, draft the manuscript, and edit the manuscript. TM helped draft the manuscript and edit the manuscript. TE served as the guarantor of this manuscript.

  • Funding TJM has received support from the National Institute on Drug Abuse of the National Institutes of Health (R01 DA048490

  • Competing interests TE: stock/equity: Vanish Therapeutics (nerve stimulator technology start-up).

  • Provenance and peer review Not commissioned; externally peer reviewed.